ATE321859T1 - B2microglobulin fusionsproteine und varianten mit hoher affinität - Google Patents

B2microglobulin fusionsproteine und varianten mit hoher affinität

Info

Publication number
ATE321859T1
ATE321859T1 AT99928376T AT99928376T ATE321859T1 AT E321859 T1 ATE321859 T1 AT E321859T1 AT 99928376 T AT99928376 T AT 99928376T AT 99928376 T AT99928376 T AT 99928376T AT E321859 T1 ATE321859 T1 AT E321859T1
Authority
AT
Austria
Prior art keywords
fusion proteins
microglobulin
beta
mhc
variants
Prior art date
Application number
AT99928376T
Other languages
English (en)
Inventor
Randall K Ribaudo
Michael Shields
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE321859T1 publication Critical patent/ATE321859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99928376T 1998-06-10 1999-06-03 B2microglobulin fusionsproteine und varianten mit hoher affinität ATE321859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8881398P 1998-06-10 1998-06-10

Publications (1)

Publication Number Publication Date
ATE321859T1 true ATE321859T1 (de) 2006-04-15

Family

ID=22213644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928376T ATE321859T1 (de) 1998-06-10 1999-06-03 B2microglobulin fusionsproteine und varianten mit hoher affinität

Country Status (5)

Country Link
EP (1) EP1086224B1 (de)
AT (1) ATE321859T1 (de)
AU (1) AU4545799A (de)
DE (1) DE69930630T2 (de)
WO (1) WO1999064597A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
WO1997035991A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
GB9929993D0 (en) * 1999-12-17 2000-02-09 Avidex Ltd Substances
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy
US20040265272A1 (en) * 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
EP2112930B1 (de) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
EP2662383A1 (de) * 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I-Antagonisten und Verfahren zur Behandlung von Infektionserkrankungen
CA2748819A1 (en) 2009-01-08 2010-07-15 Steven A. Porcelli Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PE20141212A1 (es) * 2011-06-22 2014-09-19 Hoffmann La Roche Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
CN102391377B (zh) * 2011-11-01 2013-11-06 孙嘉琳 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CA2889788A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
ES2730649T3 (es) 2013-02-08 2019-11-12 Vaccinex Inc Glicolípidos modificados y procedimientos de preparación y uso de los mismos
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3052131B1 (de) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Verfahren zur krebsbehandlung bei patienten mit erhöhtem bim-spiegel
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
EP3171896A4 (de) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5733550A (en) * 1990-05-10 1998-03-31 Dana-Farber Cancer Institute, Inc. Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
GB9307371D0 (en) * 1993-04-08 1993-06-02 Walls Alan J Fusion proteins

Also Published As

Publication number Publication date
AU4545799A (en) 1999-12-30
EP1086224A1 (de) 2001-03-28
DE69930630D1 (de) 2006-05-18
EP1086224B1 (de) 2006-03-29
DE69930630T2 (de) 2007-01-18
WO1999064597A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DE69636891D1 (de) Immunstimulierende zusammensetzung und verfahren
AU6733487A (en) Mammalian interleukin-4
DE68924162D1 (de) Stressproteine und verwendungen dafür.
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
ATE229978T1 (de) Helicobacter proteine und impstoffe
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AP2001002199A0 (en) Novel streptococcus antigens
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
AU573523B2 (en) Functional human urokinase proteins
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE69535719D1 (de) Fas-antigenbindender ligand
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
HU9402575D0 (en) Delivery and expression on a hybrid supface protein on the suprale of gram positive bacteria
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
ATE265234T1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties